CORT · NASDAQ · STOCK
Corcept Therapeutics Incorporated
$111.83
52W $28.66 – $122.21
56/100
$12.09B
215.1
0.46
Is CORT Bullish or Bearish?
Mixed.
Innellis AI committee rates Corcept Therapeutics Incorporated (CORT) Watch with a composite score of 56/100
, based on 6 analysts with 67% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +4.38 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -15.62 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 223.5 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- P/E of 223.5 is expensive by classic value standards — Value
- Price-to-book of 11.4x prices in significant intangible value — Value
- EPS declining -62.5% YoY despite any revenue growth — Growth
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 41.2% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
56/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 78%
of 192 Healthcare peers
Value Analyst
bearish
40
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 223.5 is expensive by classic value standards
Growth Analyst
neutral
42
/ 100 · Moderate confidence
Moderate growth -- present but not remarkable
− EPS declining -62.5% YoY despite any revenue growth
Technical Analyst
neutral
59
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 41.2% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
61.4
Neutral
MACD Histogram
0.460
Bullish Momentum
Trend Direction
Uptrend
Weekly: Downtrend
Market Structure
Hh Hl
Support
$69.39
Resistance
$117.20
Bollinger %B
0.75
Inside Bands
Price vs Moving Averages
EMA 9
$109.29
Above
EMA 21
$102.85
Above
EMA 50
$90.63
Above
EMA 200
$69.83
Above
Fundamental Analysis
Valuation
33
Profitability
77
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
215.1×
P/B Ratio
16.70×
PEG Ratio
-3.66
Dividend Yield
0.00%
52W High
$122.21
52W Low
$28.66
Quality & Growth
ROE
1538.3%
ROA
1191.1%
Gross Margin
9830.5%
Operating Margin
77.1%
Revenue Growth YoY
—
Debt / Equity
0.01
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 215.1 (rich relative to a 15-40x range); Price-to-book of 16.7x; PEG ratio of -3.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 15.4%; Return on assets of 11.9%; Net margin of 6.6%; Gross margin of 98.3%; Current ratio of 2.86 (healthy short-term liquidity); Debt-to-equity of 0.01; Free cash flow per share is positive (1.01); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full CORT Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →